Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05203419
Other study ID # CMHS552D12101
Secondary ID 2021-003520-33
Status Terminated
Phase Phase 1
First received
Last updated
Start date March 15, 2022
Est. completion date June 4, 2023

Study information

Verified date September 2023
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this two-part multiple ascending dose study is to evaluate the safety and tolerability of multiple doses of MHS552 in adults with mild to moderately active Systemic Lupus Erythematosus (SLE). Participants will be treated for 4 or 12 weeks followed by an 8-week follow-up period.


Description:

This was a Phase 1b, randomized, placebo-controlled, participant- and investigator- blinded, two-part non-confirmatory multiple ascending dose (MAD) study in adult patients aged 18-65 (inclusive) with active SLE disease (mild-moderate).This MAD study was planned to be conducted in two parts, Part A and Part B sequentially, but the study was terminated before Part B was initiated. In Part A, after a screening period of up to 6 weeks, participants were randomized (in a 3:1 ratio) to MHS552 or placebo administered subcutaneously (s.c.) weekly for four weeks of treatment. Part A was planned to consist of up to 3 cohorts (low, medium, high dose). Due to termination of the trial, Part A consisted of 2 cohorts (low and medium doses). Participants were followed-up during 8 weeks post last dose. The total duration of study participation of Part A was approximately 120 Days. In Part B (not started due to termination of the trial), it was planned that after a screening period of up to 28 days, approximately 12 participants to be randomized (in a 2:1 ratio) to MHS552 or placebo administered s.c. weekly for 12 weeks of treatment (dose to be confirmed).


Recruitment information / eligibility

Status Terminated
Enrollment 8
Est. completion date June 4, 2023
Est. primary completion date June 4, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Fulfills the 2019 EULAR/American College of Rheumatology (ACR) classification criteria for SLE at least 3 months prior to and at screening. - Patients with mild or moderately active SLE (SLEDAI-2K between 3 and 10, inclusive) at screening. Patients with cutaneous lupus are eligible as long as they satisfy the criteria for systemic lupus. - Patients must be on stable dose(s) of at least one of the following medications, unless the medication has been discontinued due to intolerance, inadequate response, or patient/physician decision: - steroid at a dose = 5mg but <30 mg of prednisone (or equivalent) per day, - antimalarial (hydroxychloroquine/chloroquine/quinacrine) or thalidomide, - disease modifying anti-rheumatic drugs (DMARDs): - methotrexate (MTX), - azathioprine (AZA), - mizoribine, - mycophenolate derivates. Steroid dose must be stable for at least 4 weeks prior to the first dosing. The dose of the other medications above must be stable for at least 12 weeks prior to the first dosing. If the patient is not on any medications listed above, they must have been off these medications for at least 12 weeks prior to dosing. Exclusion Criteria: - History of hypersensitivity to drugs of similar biological class, IL-2 protein analogues, or hypersensitivity to any components of the study drug, or history of severe hypersensitivity reaction or anaphylaxis to biological agents, e.g. human monoclonal antibody. - Patients with central nervous system (CNS) lupus, active Lupus Nephritis, any type of lupus flare requiring pulse steroid or immunosuppressive therapy with cyclophosphamide, rituximab, calcineurin inhibitors, or others except those permitted in the inclusion criteria. - Systemic autoimmune disease other than lupus, which would interfere with participation in the study according to the Investigator's judgement. Treated, stable Hashimoto's thyroiditis is not exclusionary. - Any of the following abnormal laboratory values at Screening or pre-dose Day 1 assessment: Hemoglobin levels below 8.0 g/dL at screening Eosinophil count >700 mm3 or >2 X Upper Limit of Normal (ULN), whichever is lower. - History of capillary leak syndrome (CLS). Other protocol-defined inclusion/exclusion criteria may apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MHS552
MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
Placebo
Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)

Locations

Country Name City State
Germany Novartis Investigative Site Berlin

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs) Numbers of participants with AEs and SAEs, and other safety data such as vital signs, electrocardiograms (ECG) and laboratory results Part A: up to 12 weeks; Part B: up to 20 weeks
Secondary Area Under Plasma Concentration-time Curve calculated to the end of a dosing interval (AUCtau) for MHS552 Characterize the AUCtau profile following multiple doses of MHS552 Part A: up to Day 78; Part B: up to Day 134
Secondary Maximum Observed Blood Concentrations (Cmax) for MHS552 Characterize the Cmax profile following multiple doses of MHS552 Part A: up to Day 78; Part B: up to Day 134
Secondary Time to Reach Maximum Blood Concentrations (Tmax) of MHS552 Characterize the Tmax profile profile following multiple doses of MHS552 Part A: up to Day 78; Part B: up to Day 134
See also
  Status Clinical Trial Phase
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Recruiting NCT05967520 - JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus Phase 2
Completed NCT02875691 - Effect of Green Tea on Treatment of Lupus Phase 2
Completed NCT02922114 - Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients N/A
Withdrawn NCT01702038 - Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE Phase 2
Terminated NCT00368264 - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Phase 2/Phase 3
Completed NCT00094380 - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Phase 1/Phase 2
Completed NCT00065806 - Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Phase 3
Completed NCT00005436 - Lupus Cohort--Thrombotic Events and Coronary Artery Disease N/A
Recruiting NCT03543839 - Trial of Belimumab in Early Lupus Phase 4
Completed NCT03098823 - A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Phase 4
Recruiting NCT05899907 - Efficacy and Safety of Telitacicept in Early SLE Phase 4
Completed NCT04956484 - Belimumab In Early Systemic Lupus Erythematosus Phase 4
Completed NCT05326841 - Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients . Phase 3
Completed NCT02655640 - The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis N/A
Completed NCT02034344 - A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers Phase 0
Terminated NCT00089804 - Study of LJP 394 in Lupus Patients With History of Renal Disease Phase 3
Completed NCT00071487 - Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE) Phase 2
Completed NCT02349061 - A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus Phase 2
Recruiting NCT05636670 - Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease

External Links